Larry Ereshefsky, PharmD, provided Phase 3 data on brilaroxazine for schizophrenia.

Published Date: 09 May 2024

Phase 3 RECOVER trial evaluating brilaroxazine at 50 mg and 15 mg for acute schizophrenia was reviewed by Larry Ereshefsky, PharmD, in an interview with HCPLive.

Read Full News

Latest News

Integrated HIV Prevention: Bridging Mental Health Care and Sexual Wellness

Integrated HIV Prevention: Bridging Mental Health Care and Sexual Wellness

HIV Prevention and Mental Health: A Person-Centered Approach to PrEP

HIV Prevention and Mental Health: A Person-Centered Approach to PrEP

Clinical Connections in HIV Prevention: Integrating PrEP Into Mental Health Settings

Clinical Connections in HIV Prevention: Integrating PrEP Into Mental Health Settings

APA: American Psychiatric Association

Psych Congress: Psychiatry & Behavioral Health Learning Network

Psychedelic Retreats, a Booming Business With Few Safety Guardrails

Many carry "potential for physical, psychological, and interpersonal harms," researchers say

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Integrated HIV Prevention: Bridging Mental Health Care and Sexual Wellness

HIV Prevention and Mental Health: A Person-Centered Approach to PrEP

Clinical Connections in HIV Prevention: Integrating PrEP Into Mental Health Settings

Many carry "potential for physical, psychological, and interpersonal harms," researchers say

News All Time

Ketamine Quickly Reduced Suicidal and Depressive Symptoms, Meta-Analysis Suggests

Experts express concerns about unblinding effects in randomized trials

Psych Trial Halted After Death; Curbing Phone Addiction; Most Worried Racial Group

News and commentary from the psychiatry world

AI Company Sued Over Chatbots Allegedly Claiming to Be Licensed Doctors

The case comes amid calls for more chatbot regulations

Unexplained Catatonia: What's Behind Woman's Sudden Symptoms?

Recent history of insomnia could be a clue

What's Causing the Dyspnea, Choking Feeling in Woman With Schizophrenia?

Initial misdiagnosis of panic attack led to a potentially fatal treatment delay

American Positive for Hantavirus; RFK Jr. Weighed SSRI Ban? Ant-Infested Hospital

— Health news and commentary gathered by MedPage Today staff

Where Is the Off Ramp for Psychotropic Medications?

We need better standards for when and how to taper or discontinue these drugs

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

AI Scribes Reduce Physician Burnout Within 30 Days, With Lee Schwamm, MD Lee Schwamm, MD

Physicians experience significant challenges with increasing administrative burdens impacting patient care. Study shows AI scribes can help reduce burnout.

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

Adding CBT to Quetiapine Significantly Reduces Suicide Risk in Mood Disorders

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDD

Recommended News For You

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

Indoor hydroponic gardening can improve mental health and quality of life for cancer patients

Radiation from CT scans could account for 5% of all cancer cases a year, study suggests

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

Recommended Articles For You

The Significance of APTT Blood Test Results for Detecting Coagulation Disorders 

Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis 

The Pros and Cons of Using Cyclophosphamide in Cancer Treatment  

Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

1.

The benefits and risks of taking fludrocortisone for adrenal insufficiency 

2.

Ultimate Guide to Oncology Services in the USA

3.

Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies

4.

Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools

5.

Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Oropharyngeal Cancer in Relation to HPV Status

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

3.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

4.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot